AI assistant
ABBOTT LABORATORIES — Director's Dealing 2019
Jun 6, 2019
29777_dirs_2019-06-05_1724f6c8-d484-430b-bcdb-7ebd1bf76149.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2019-06-03
Reporting Person: Wainer Andrea F (Executive Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-06-03 | Common shares without par value | A | 11967 | — | Acquired | 42448 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-06-03 | Option (right to buy) | $76.12 | A | 62725 | Acquired | 2029-06-02 | Common shares (62725) | Direct |
Footnotes
F1: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.
F2: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,908 on June 3, 2020, 20,908 on June 3, 2021, and 20,909 on June 3, 2022.